Shenzhen-based biotechnology company Rhegen Bio, specializing in mRNA technology, has reportedly raised RMB 100 million (USD 14.7 million) in a pre-Series B financing round. The funding was led by Fer-Capital Investment, with participation from Sequoia Capital China and other existing investors. The proceeds will be used to support clinical trials and the development of industrialization infrastructure.
Company Overview and Pipeline
Rhegen Bio operates research and development (R&D), manufacturing, and clinical regulatory filing centers in Wuhan and Shanghai. The company boasts a diverse product pipeline consisting of dozens of products, covering infectious disease vaccines, tumor immunotherapies, and protein replacement therapies. Notably, Rhegen Bio’s RH109 is the world’s first COVID-19 freeze-dried vaccine, which has entered clinical trials in the Philippines, New Zealand, the Chinese mainland, and Hong Kong.
Future Outlook
The pre-Series B financing round positions Rhegen Bio to accelerate its clinical development and expand its industrialization capabilities. With robust financial backing and a strong product pipeline, Rhegen Bio is poised to make a significant impact in the field of mRNA technology. The company’s innovative approach to vaccine development and immunotherapy underscores its dedication to advancing healthcare solutions globally.-Fineline Info & Tech
